Phase II Study of LM-24C5
ConditionAdvanced Solid Tumor Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorLaNova Medicines Limited
About this trial
This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor
Eligibility criteria
Qualifiers
Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
Aged 18-80 years old (including boundary values) , male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Life expectancy ≥ 3 months.
Disqualifiers
Subjects with a history of other malignancies within 5 years prior to first dosing of LM-24C5, excluding cured squamous cell carcinoma of the skin, basal cell carcinoma, non-muscle-invasive bladder cancer, or localized low-risk prostate cancer, carcinoma in situ of the cervix/breast, and other malignancies deemed by the investigator to potentially benefit from participation in this study.
Subjects who have received other anti-tumor treatments before the first dosing of LM-24C5.
Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis.
Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
Trial design
Treatments tested in this trial
- LM-24C5
- LM-24C5
Treatment groups
130 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov